

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: YAN et al.

Art Unit: 1642

Serial No. 09/770,689

Examiner: K. Canella

Filed: January 29, 2001

Atty. Docket: CL001079

For: ISOLATED HUMAN RAS-LIKE PROTEINS, NUCLEIC ACID MOLECULES ENCODING THESE HUMAN RAS-LIKE PROTEINS, AND USES THEREOF

Statement Regarding Duty Of Disclose Information Material To Patentability Under 37 CFR 1.56 (a) and (b)

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

RECEIVED

Sir:

This statement is to inform the United States of Patent and Trademark Office (1992) Applicants and their representative have made a good faith effort in searching prior art relating to this invention.

No prior art material to patentability of the present invention has been found. The closest information associated with the invention is disclosed in Figures 1 and 2 in the top BLAST search results. However, this information, by itself or in combination with other information, does not constitute a prima facie case of unpatentability of any of the pending claims. Thus, it does not defeat the novelty of the present invention and the actual underlying references for the top BLAST hits are not being provided.

Respectfully submitted,

CELERA GENOMICS

Date: April 26, 2002

Celera Genomics Corporation 45 West Gude Drive, C2-4#20 Rockville, MD 20850

Tel: 240-453-3812 Fax: 240-453-3084

PTO/SB/21 (08-00) Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. 09/770.689 **Application Number TRANSMITTAL** 01/29/2001 Filing Date Chunhua YAN et al. **FORM** First Named Inventor 1642 **Group Art Unit** (to be used for all correspondence after initial filing) K. Canella **Examiner Name** CL001079 Attorney Docket Number Total Number of Pages in This Submission (check all that apply) **ENCLOSURES** After Allowance Communication Assignment Papers no fee due to Group Fee Transmittal Form (for an Application) 1 Appeal Communication to Board Drawing(s) Fee Attached of Appeals and Interferences Appeal Communication to Group Licensing-related Papers Amendment / Reply (Appeal Notice, Brief, Reply Brief) 1 Petition Proprietary Information After Final Petition to Convert to a **Provisional Application** Status Letter Affidavits/declaration(s) Power of Attorney, Revocation Other Enclosure(s) (please Change of Correspondence Address identify below): Extension of Time Request Statement Regarding Duty of Disclosure Terminal Disclaimer **Express Abandonment Request** Request for Refund RECEIVED Information Disclosure Statement CD, Number of CD(s) -Certified Copy of Priority APR 2:9 2002 Remarks Document(s) **TECH CENTER 1600/2900** Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Justin D. Karjala, Reg. No. 43,704 Individual name Signature 04/26/2002 Date CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: Typed or printed name

Signature Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Date

PTO/SB/17 (10-01)
Approved for use through 10/31/2002. OMB 0651-0032

Under the Paperwork Reduction Act of 1995, no per	sons are required to	U,S, Patent and Tra respond to a collection of infor	mation unless it disolars a valid OMB control number				
		Complete if Known					
FFEE TRANSMI	IIAL	Application Number	09/770,689				
· 6		Filing Date	January 29, 2001				
for FY 200	2	First Named Inventor	Chunhua YAN et al.				
2002	vision.	Examiner Name	K. Canella				
Patent fees are subject to annual re	VISION.	Group Art Unit	1642				
MISTAL AMOUNT OF PAYMENT (\$)	0	Attorney Docket No.	CL001079				

METHOD OF PAYMENT				FE	E CALCULATION (continued)			
Ti O wind in heady sufficient to charge	3. Al	DDIT	ONA	L FE	ES	- 1		
1. X indicated fees and credit any overpayments to:		3. ADDITIONAL FEES Large Small						
Deposit Account Number 50-0970	Fee Code		y Fee Code	Entil Fee	y Fee Description	Fee Paid		
Deposit Account Celera Genomics	105	130	205	6 5	Surcharge - late filing fee or oath			
Name	127	50	227	25	Surcharge - late provisional filing fee or cover sheet			
Munder 37 CFR 1.16 and 1.17 Applicant claims small entity status.	139	130		130	Non-English specification			
See 37 CFR 1.27	147	2,520			For filing a request for ex parte reexamination			
2. Payment Enclosed: Check Credit card Order Other		920-		920*	Requesting publication of SIR prior to Examiner action			
		1,840*	113	1,840	Requesting publication of SIR after Examiner action			
FEE CALCULATION	115	110	215	55	Extension for reply within first month			
1. BASIC FILING FEE	116	400	216	200	Extension for reply within second month			
Large Entity Small Entity Fee Fee Fee Fee Description	117	920	217	460	Extension for reply within third month	CEIMF		
Code (\$) Code (\$) Fee Paid	118	1,440	218	720	Extension for reply within fourth month			
101 740 201 370 Utility filing fee	1	1,960	228	980	Extension for reply within fifth month	R 2 9 200		
106 330 206 165 Design filing fee	119	320	219	160	Notice of Appeal			
107 510 207 255 Plant filing fee	120	320	220	160	Filing a brief in support of an apper FCH CI Request for oral hearing	ENITED AND		
108 740 208 370 Reissue filing fee	121	280	221	140	Request for oral hearing	FINIEW TOOL		
114 160 214 80 Provisional filing fee	138	1,510	138	1,510	Petition to institute a public use proceeding			
SUBTOTAL (1) (\$) 0	140	110	240	55	Petition to revive - unavoidable			
2. EXTRA CLAIM FEES	141	1,280	241	640	Petition to revive - unintentional	<u> </u>		
Fee from Extra Claims below Fee Paic	142	1,280	242	640	Utility issue fee (or reissue)	I		
Total Claims 10 -20** = 0 x 18 = 0	143	460	243	230	Design issue fee			
Independent 3 - 3** = 0 x 84 = 0	144	620	244	310	Plant issue fee			
Multiple Dependent 270 = 0	122	130	122	130	Petitions to the Commissioner	 		
	123	50	123	50	Processing fee under 37 CFR 1.17(q)			
Large Entity Small Entity	126	180	126	180	Submission of Information Disclosure Stmt	<u> </u>		
Fee Fee Fee Fee Fee Description Code (\$) Code (\$) 103 18 203 9 Claims in excess of 20	581	40	581	40	Recording each patent assignment per property (times number of properties)			
103 18 203 9 Claims in excess of 20 102 84 202 42 Independent claims in excess of 3	146	740	246	370	Filing a submission after final rejection (37 CFR § 1.129(a))			
104 280 204 140 Multiple dependent claim, if not paid	149	740	249	370	For each additional invention to be			
109 84 209 42 ** Reissue independent claims over original patent	'"	, 40	2-3		examined (37 CFR § 1.129(b))			
110 18 210 9 ** Reissue claims in excess of 20		740	279	370	Request for Continued Examination (RCE)			
and over original patent	169	900	169	900	Request for expedited examination of a design application			
SUBTOTAL (2) (\$) 0	Othe	er fee (:	specif	y)		<u>-</u>		
**or number previously paid, if greater; For Reissues, see above *Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 0								
			-		Complete (if applicable)			

SUBMITTED BY		Complete (if applicable)			
Name (Print/Type)	Justin D. Karjala	Registration No. (Attorney/Agent)	43,704	Telephone	240-453-3812
Signature	Cart to Kent			Date	26-Apr-02

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.